TV News LIES

Sunday, May 28th

Last update05:20:13 AM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

More...


Most Recent Related Stories...


CBO: House Obamacare repeal bill would leave 23 million more uninsured

CBO reporet: 23 million Americans would lose health careRoughly 23 million more people would be uninsured over a decade if the House-passed Republican Obamacare...

Use of 'light' cigarettes linked to rise in lung adenocarcinoma

Light cigarettes lead to more lung adenocarcinomaStudy shows so-called "light" cigarettes do not benefit health and may contribute to the increased risk...

Magic mushrooms are the safest recreational drug, study says

Magic mushrooms safest form of recreational drugA new survey found that when it comes to recreational drug use, magic mushrooms appear to...

'Global gag rule' reinstated by Trump, curbing NGO abortion services abroad

Global gag rulePresident Donald Trump’s administration announced the details Monday of the president’s unprecedented international anti-abortion policy, which...
 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!